Who are Shuxinin injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Danhong injection, Xingnaojing injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/shuxinin-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Shuxinin injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shuxinin injection (Shuxinin injection) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine injection. Area: Pain management, Cardiovascular.

marketed Traditional Chinese medicine injection Pain management, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Shuxinin injection (Shuxinin injection) — Peking University Third Hospital. Shuxinin is a traditional Chinese medicine injection that promotes blood circulation and removes blood stasis to alleviate pain and improve microcirculation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Shuxinin injection TARGET	Shuxinin injection	Peking University Third Hospital	marketed	Traditional Chinese medicine injection
Danhong injection	Danhong injection	China Academy of Chinese Medical Sciences	marketed	Traditional Chinese medicine injection
Xingnaojing injection	Xingnaojing injection	Dongzhimen Hospital, Beijing	marketed	Traditional Chinese medicine injection

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine injection class)

China Academy of Chinese Medical Sciences · 1 drug in this class
Dongzhimen Hospital, Beijing · 1 drug in this class
Peking University Third Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Shuxinin injection — Competitive Intelligence Brief. https://druglandscape.com/ci/shuxinin-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing